The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior to market open on Monday, November 19, 2012.
The following six securities will be added to the Index: Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), Synageva BioPharma Corp. (Nasdaq:GEVA), Merrimack Pharmaceuticals, Inc.(Nasdaq:MACK), Supernus Pharmaceuticals, Inc.(Nasdaq:SUPN), XOMA Corporation (Nasdaq:XOMA) and Zogenix, Inc. (Nasdaq:ZGNX).
The Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. For more information about the NASDAQ Biotechnology Index, including detailed eligibility criteria, visit https://indexes.nasdaqomx.com/.
As a result of the re-ranking, the following two securities will be removed from the Index: Maxygen, Inc. (Nasdaq:MAXY) and Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX).
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSM Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.
